UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study

Annals of oncology, 2022-05, Vol.33 (5), p.534-543

2022

Volltextzugriff (PDF)

Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials

The Lancet (British edition), 2012-02, Vol.379 (9814), p.432-444

2012

Volltextzugriff (PDF)

Immune modulation of pathologic complete response after neoadjuvant HER2-directed therapies in the NeoSphere trial

Annals of oncology, 2015-12, Vol.26 (12), p.2429-2436

2015

Volltextzugriff (PDF)

The influential and inspirational Gianni Bonadonna's life commitment to evidence-based cancer medicine

Annals of oncology, 2016-01, Vol.27 (1), p.6-8

2016

Volltextzugriff (PDF)

Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation

Leukemia, 2006-09, Vol.20 (9), p.1533-1538

2006

Volltextzugriff (PDF)

Second malignancy risk associated with treatment of Hodgkin's lymphoma: meta-analysis of the randomised trials

Annals of oncology, 2006-12, Vol.17 (12), p.1749-1760

2006

Volltextzugriff (PDF)

The dissection of internal mammary nodes does not improve the survival of breast cancer patients. 30-year results of a randomised trial

European journal of cancer (1990), 1999-09, Vol.35 (9), p.1320-1325

1999

Volltextzugriff (PDF)

PATINA: A randomized, open label, phase III trial to evaluate the efficacy and safety of palbociclib + Anti-HER2 therapy + endocrine therapy (ET) vs. anti-HER2 therapy + ET after induction treatment for hormone receptor positive (HR+)/HER2-positive metastatic breast cancer (MBC)

Annals of oncology, 2018-10, Vol.29, p.viii121-viii121

2018

Volltextzugriff (PDF)

Long term results of ASTER study, a single Institution phase II trial of sequential chemotherapy (CT) for operable breast cancer (BC)

Annals of oncology, 2017-10, Vol.28 Suppl 6, p.vi34

2017

Volltextzugriff (PDF)

Research-based PAM50 predicts risk of relapse in residual disease after anti-HER2 therapies

Annals of oncology, 2018-10, Vol.29, p.viii61-viii61

2018

Volltextzugriff (PDF)

Management of breast cancer after Hodgkin’s lymphoma and paediatric cancer

European journal of cancer (1990), 2015-09, Vol.51 (13), p.1667-1674

2015

Volltextzugriff (PDF)

Does surgery modify growth kinetics of breast cancer micrometastases?

British journal of cancer, 2001-08, Vol.85 (4), p.490-492

2001

Volltextzugriff (PDF)

Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute

Journal of clinical oncology, 1998-01, Vol.16 (1), p.93-100

1998

Volltextzugriff (PDF)

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis

The Lancet (British edition), 2014-07, Vol.384 (9938), p.164-172

2014

Volltextzugriff (PDF)

Surgery following neoadjuvant therapy in patients with HER2-positive locally advanced or inflammatory breast cancer participating in the NeOAdjuvant Herceptin (NOAH) study

European journal of surgical oncology, 2011-10, Vol.37 (10), p.856-863

2011

Volltextzugriff (PDF)

Long-Term Cardiac Sequelae in Operable Breast Cancer Patients Given Adjuvant Chemotherapy With or Without Doxorubicin and Breast Irradiation

Journal of clinical oncology, 2001-01, Vol.19 (1), p.37-43

2001

Volltextzugriff (PDF)

Breast cancer recurrence dynamics following adjuvant CMF is consistent with tumor dormancy and mastectomy-driven acceleration of the metastatic process

Annals of oncology, 2005-09, Vol.16 (9), p.1449-1457

2005

Volltextzugriff (PDF)

Response to Cyclophosphamide, Methotrexate, and Fluorouracil in Lymph Node–Positive Breast Cancer According to HER2 Overexpression and Other Tumor Biologic Variables

Journal of clinical oncology, 2001-01, Vol.19 (2), p.329-335

2001

Volltextzugriff (PDF)

Effect of Age and Previous Autologous Transplantation on Nonrelapse Mortality and Survival in Patients Treated With Reduced-Intensity Conditioning and Allografting for Advanced Hematologic Malignancies

Journal of clinical oncology, 2005-09, Vol.23 (27), p.6690-6698

2005

Volltextzugriff (PDF)

Results of a randomized trial comparing high-dose chemotherapy plus Auto-SCT and R-FC in CLL at diagnosis

Bone marrow transplantation (Basingstoke), 2014-04, Vol.49 (4), p.485-491

2014

Volltextzugriff (PDF)

PD-0526: Relationship between extension of radiation fields and second primary cancers in early stage Hodgkinís Lymphoma

Radiotherapy and oncology, 2013-03, Vol.106, p.S202-S203

2013

Volltextzugriff (PDF)

Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials

The Lancet (British edition), 2014-06, Vol.383 (9935), p.2127-2135

2014

Volltextzugriff (PDF)

Outcome of patients with Hodgkin's disease failing after primary MOPP-ABVD

Journal of clinical oncology, 1997-02, Vol.15 (2), p.528-534

1997

Volltextzugriff (PDF)

HER2 Status: A Statistician's View

Annals of oncology, 2001, Vol.12 (suppl-1), p.S29-S34

VALAGUSSA, P

2001

Volltextzugriff (PDF)

Efficacy, toxicity, and applicability of high-dose sequential chemotherapy as adjuvant treatment in operable breast cancer with 10 or more involved axillary nodes: five-year results

Journal of clinical oncology, 1997-06, Vol.15 (6), p.2312-2321

1997

Volltextzugriff (PDF)

1 – 25 von 391

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(348)
Mit Volltextzugriff
(301)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Humans
(264)
Female
(218)
Science & Technology
(211)
Life Sciences & Biomedicine
(207)
Middle Aged
(143)
Oncology
(140)
Adult
(135)
Biological And Medical Sciences
(117)
Medical Sciences
(117)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(108)
Breast Neoplasms - Drug Therapy
(107)
Aged
(99)
Male
(74)
Breast Neoplasms - Surgery
(71)
Combined Modality Therapy
(69)
Chemotherapy
(66)
Pharmacology. Drug Treatments
(66)
Cyclophosphamide - Administration & Dosage
(60)
Prognosis
(59)
Antineoplastic Agents
(57)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Annals Of Oncology
(51)
Journal Of Clinical Oncology
(50)
European Journal Of Cancer
(23)
Recent Results In Cancer Research
(18)
The Lancet
(17)
Breast Cancer Research And Treatment
(13)
Cancer Research
(13)
Seminars In Oncology
(12)
Tumori
(9)
Cancer
(8)

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study

Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials

Immune modulation of pathologic complete response after neoadjuvant HER2-directed therapies in the NeoSphere trial

The influential and inspirational Gianni Bonadonna's life commitment to evidence-based cancer medicine

Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation

Second malignancy risk associated with treatment of Hodgkin's lymphoma: meta-analysis of the randomised trials

The dissection of internal mammary nodes does not improve the survival of breast cancer patients. 30-year results of a randomised trial

PATINA: A randomized, open label, phase III trial to evaluate the efficacy and safety of palbociclib + Anti-HER2 therapy + endocrine therapy (ET) vs. anti-HER2 therapy + ET after induction treatment for hormone receptor positive (HR+)/HER2-positive metastatic breast cancer (MBC)

Long term results of ASTER study, a single Institution phase II trial of sequential chemotherapy (CT) for operable breast cancer (BC)

Research-based PAM50 predicts risk of relapse in residual disease after anti-HER2 therapies

Management of breast cancer after Hodgkin’s lymphoma and paediatric cancer

Does surgery modify growth kinetics of breast cancer micrometastases?

Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis

Surgery following neoadjuvant therapy in patients with HER2-positive locally advanced or inflammatory breast cancer participating in the NeOAdjuvant Herceptin (NOAH) study

Long-Term Cardiac Sequelae in Operable Breast Cancer Patients Given Adjuvant Chemotherapy With or Without Doxorubicin and Breast Irradiation

Breast cancer recurrence dynamics following adjuvant CMF is consistent with tumor dormancy and mastectomy-driven acceleration of the metastatic process

Response to Cyclophosphamide, Methotrexate, and Fluorouracil in Lymph Node–Positive Breast Cancer According to HER2 Overexpression and Other Tumor Biologic Variables

Effect of Age and Previous Autologous Transplantation on Nonrelapse Mortality and Survival in Patients Treated With Reduced-Intensity Conditioning and Allografting for Advanced Hematologic Malignancies

Results of a randomized trial comparing high-dose chemotherapy plus Auto-SCT and R-FC in CLL at diagnosis

PD-0526: Relationship between extension of radiation fields and second primary cancers in early stage Hodgkinís Lymphoma

Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials

Outcome of patients with Hodgkin's disease failing after primary MOPP-ABVD

HER2 Status: A Statistician's View

Efficacy, toxicity, and applicability of high-dose sequential chemotherapy as adjuvant treatment in operable breast cancer with 10 or more involved axillary nodes: five-year results

Suchergebnisse filtern